nepafenac has been researched along with Disease Models, Animal in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Chastain, JE; Chemuturi, NV; Curtis, MA; Dahlin, DC; Gadd, ME; Kapin, MA; Markwardt, KL; Sanders, ME | 1 |
| Bingaman, DP; Clark, ML; Penn, JS; Yang, R; Yanni, SE | 1 |
| Chuck, RS; Zhang, C; Zhu, L | 1 |
| Ando, A; Bingaman, DP; Campochiaro, PA; Melia, MB; Mori, K; Nambu, H; Oshima, Y; Saishin, Y; Takahashi, K; Yamamoto, S | 1 |
5 other study(ies) available for nepafenac and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Chromatography, High Pressure Liquid; Disease Models, Animal; Instillation, Drug; Macaca fascicularis; Male; Ophthalmic Solutions; Phenylacetates; Posterior Eye Segment; Rabbits; Tissue Distribution; Uveitis, Posterior | 2016 |
The effects of nepafenac and amfenac on retinal angiogenesis.
Topics: Analysis of Variance; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Celecoxib; Cell Proliferation; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; Epithelial Cells; Gene Expression Regulation; Humans; Neuroglia; Oxygen; Phenylacetates; Prostaglandins; Pyrazoles; Rats; Rats, Long-Evans; Rats, Sprague-Dawley; Retina; Retinal Neovascularization; Retinal Vessels; Sulfonamides; Vascular Endothelial Growth Factor A | 2010 |
Topical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Botulinum Toxins; Botulinum Toxins, Type A; Conjunctiva; Cornea; Disease Models, Animal; Dry Eye Syndromes; Female; Fluorescein; Fluorometholone; Glucocorticoids; Interleukin-1beta; Ketorolac; Lacrimal Apparatus; Mice; Mice, Inbred CBA; Ophthalmic Solutions; Phenylacetates; Tears; Tumor Necrosis Factor-alpha | 2012 |
Topical nepafenac inhibits ocular neovascularization.
Topics: Administration, Topical; Animals; Benzeneacetamides; Choroidal Neovascularization; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Models, Animal; Endothelial Growth Factors; Intercellular Signaling Peptides and Proteins; Isoenzymes; Ketorolac Tromethamine; Lymphokines; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Transgenic; Ophthalmic Solutions; Phenylacetates; Prodrugs; Prostaglandin-Endoperoxide Synthases; Retinal Neovascularization; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |